Company to feature in Microsoft’s shared ‘Digital Hub’ exhibition space at meeting, in Frankfurt
Cambridge, UK - 18 August 2022 - Today, Eagle Genomics, the software platform business pioneering the application of network science to biology, announced its attendance at international tradeshow ACHEMA 2022 in Frankfurt, Germany next week (22-26 August) as a Microsoft Showcase Partner. Eagle Genomics will be featured in Microsoft’s ‘Digital Hub’ Innovation space under the theme “Eagle Genomics and Microsoft: Working Together Towards the Bio Revolution.” Other Innovation Partners to be featured in the Digital Hub include Process Automation Solutions, AVEVA, Rescale, Sight Machine, SAS, PTC, SoftwareONE, Crayon, MML, Robotron, MobiLab and Zühlke.
ACHEMA is the annual tradeshow for manufacturers and service providers in the chemical, pharmaceutical, biotech, energy and environmental services sectors, with exhibitors from over 50 countries. Guenter Schneider, Commercial Director, and Sven Sewitz, Director of Biodata Innovation will be representing Eagle Genomics at the event.
As Microsoft’s first microbiome-focused partner, Eagle Genomics and Microsoft have been working together to help some of the world’s largest organizations to engage with, and participate in, the Bio Revolution. This involves helping to drive innovation and the growth of the bioeconomy by enabling the networking of microbiome science.
In 2019, Eagle Genomics graduated from the Microsoft Scale-Up programme (see video here), and achieved full co-sell and One Commercial Partner (OCP) status in a business partnership with Microsoft Azure. In 2018 it announced a partnership with Microsoft Genomics to accelerate the computational capabilities for microbiome science, and in 2019 was selected to join the Microsoft AI Factory based at the world-renowned Station F start-up campus in Paris.
Eagle Genomics’ AI-augmented knowledge discovery platform, e[datascientist]™, transforms the scientist’s journey from hypothesis through insight, unifying constellations of complex, multi-dimensional data to explore and extract networks of relationships unable to be detected by humans alone. The scalable platform harnesses AI to analyze complex microbiome data at scale, delivering new insights, and enabling organizations such as Unilever to assess the viability, efficacy and safety of their products, as well as generate new, robust product claims.